Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
Myeloma
-
-
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
-
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
-
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
-
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
-
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
-
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
-
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
-
Blood Cancer Awareness Month: How Alliance Clinical Trials Are Helping Improve Treatments, Early Detection and Survivorship
September is Blood Cancer Awareness Month, and the Alliance for Clinical Trials in Oncology is highlighting the importance of clinical research that advances treatments, explores earlier cancer detection, and improves the lives of people living with and beyond cancer. More than 192,000 people in the United States are expected to be diagnosed with a blood…
-
Sharing News from the Alliance in the Media: July Media Mentions
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. More than just news mentions, these media stories serve…